Roivant updates Immunovant Graves’ Disease program

Rhea-AI Filing Summary

Roivant Sciences Ltd. reported that it has provided an update on the Graves’ Disease development program at its subsidiary, Immunovant, Inc. The company issued a press release and made it available as an exhibit, focusing on Immunovant’s proof-of-concept study in Graves’ Disease.

Roivant also posted an investor presentation covering the update on Immunovant’s Graves’ Disease proof-of-concept study on its investor relations website and scheduled a conference call and webcast to discuss remission data from Immunovant’s Graves’ Disease trial at 4:30 p.m. E.D.T. Both the press release and the presentation are included as exhibits to the report, while the website content itself is not incorporated.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Roivant Sciences Ltd. (ROIV) disclose about Graves’ Disease?

Roivant Sciences Ltd. reported that its subsidiary, Immunovant, Inc., provided an update on its Graves’ Disease development program, including information from a proof-of-concept study.

How is Immunovant involved in Roivant Sciences Ltd. (ROIV)’s Graves’ Disease program?

Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. and is responsible for conducting the Graves’ Disease proof-of-concept study discussed in the update.

What materials about Graves’ Disease did Roivant (ROIV) make available to investors?

Roivant made a press release and an investor presentation available as exhibits, both dated September 3, 2025, describing the update on Immunovant’s Graves’ Disease program.

Did Roivant Sciences Ltd. (ROIV) schedule a call about the Graves’ Disease trial?

Yes. Roivant stated it will host a conference call and webcast at 4:30 p.m. E.D.T. to discuss remission data from Immunovant’s Graves’ Disease trial.

Where can investors find the Graves’ Disease presentation for Roivant (ROIV)?

Roivant posted the presentation on the “Events & Presentations” page of its investor relations website at https://investor.roivant.com, and also filed it as an exhibit.

Is the Graves’ Disease information in Roivant’s website incorporated into its other filings?

Roivant stated that the contents of its website referenced in the report are not incorporated into the report or other filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 01:38 PM Learn about SEC filing dates

false0001635088NASDAQ00016350882025-09-032025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 3, 2025

Roivant Sciences Ltd.

(Exact name of registrant as specified in its charter)

Bermuda	001-40782	98-1173944
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

(Address of principal executive offices, and Zip Code)

+44 207 400-3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share		ROIV		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 3, 2025, Roivant Sciences Ltd. (the “Company”) issued a press release providing an update on the Graves’ Disease (“GD”) development program at its subsidiary, Immunovant, Inc. (“Immunovant”). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 8.01. Other Events.

On September 3, 2025, the Company posted a presentation regarding the update on Immunovant’s GD proof-of-concept study on the “Events & Presentations” page of its investor relations website at https://investor.roivant.com and will host a conference call and webcast to discuss the remission data from Immunovant’s GD trial at 4:30 p.m. E.D.T. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Press Release, dated September 3, 2025.
99.2		Presentation, dated September 3, 2025.
104		Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
By:	/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: September 3, 2025